Conjunctival Flora Patterns After Serial Intravitreal Injections in Diabetic Patients
1 other identifier
interventional
50
1 country
1
Brief Summary
The aim of this study is to investigate the conjunctival bacterial flora and antibiotic resistance patterns following serial intravitreal injections of anti-VEGF in diabetic patients, using a povidone-iodine preparation without preinjection or postinjection topical antibiotics.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jan 2015
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 1, 2015
CompletedStudy Start
First participant enrolled
January 1, 2015
CompletedFirst Posted
Study publicly available on registry
January 14, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2016
CompletedFebruary 20, 2015
February 1, 2015
11 months
January 1, 2015
February 19, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change of conjunctival flora and bacterial resistance
4 month
Study Arms (1)
Diabetic patients
EXPERIMENTALPatients with Diabetes Mellitus and macular edema who were determined by their treating physician to require at least 3 serial injections with an anti-Vascular epithelial growth factor (VEGF). Prior to each injection a use of povidone-iodine 4% drops will be performed to clean the conjunctival sac
Interventions
Prior to each injection and before the use of povidone-iodine drops, a conjunctival culture will be taken
Eligibility Criteria
You may qualify if:
- age above 18
- patients with diabetes mellitus
- patients with diabetic macular edema
You may not qualify if:
- patients who had received a prior intraocular injection in either eye,
- current use of contact lenses,
- chronic use of any ophthalmic medication,
- ocular surgery within the past 6 months,
- use of systemic antibiotics within the past 6 months,
- known allergy or contraindication to povidone-iodine or proparacaine.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sheba Medical Centerlead
- Assaf-Harofeh Medical Centercollaborator
Study Sites (1)
Sheba Medical Center
Tel Litwinsky, Non-US Resident, 52621, Israel
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Irit Barequet, MD
Sheba medical center, Ophthalmology department
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Head of cornea unit, Ophthalmology department
Study Record Dates
First Submitted
January 1, 2015
First Posted
January 14, 2015
Study Start
January 1, 2015
Primary Completion
December 1, 2015
Study Completion
January 1, 2016
Last Updated
February 20, 2015
Record last verified: 2015-02